ArticleFrontiers in oncology2021

Evaluation of Epigallocatechin-3-Gallate as a Radioprotective Agent During Radiotherapy of Lung Cancer Patients: A 5-Year Survival Analysis of a Phase 2 Study.

Wanqi Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.